tbuckley/cabot-search huggingface dataset:
Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303
Authors: Wyndham H. Wilson, Jung sin-Ho, Brandelyn Nicole Pitcher, Eric D Hsi, Jonathan Friedberg, Bruce Cheson, Nancy L Bartlett, Scott Smith, Nina Wagner Johnston, Brad S Kahl, Louis M. Staudt, Kristie Blum, Jeremy Abramson, Oliver W Press, Richard I. Fisher, Kristy L. Richards, Heiko Schoder, Julie E Chang, Andrew D. Zelenetz, John P. Leonard
Journal: Blood (2016)
Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience
Authors: V. Fanotto, C. Fontanella, S. Cordio, G. Pasquini, M. Baretti, R. Filippi, G. Rosati, D. Santini, R. Giampieri, S. Di Donato, G. Tomasello, O. Brunetti, M. Caporale, F. Bergamo, A. Avallone, M. Scartozzi, E.S. Lutrino, D. Melisi, L. Antonuzzo, A. Pellegrino, G. Aprile
Journal: Annals of Oncology (2016)
Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: A pilot randomized study of high-dose vitamin D 3 administration
Authors: Jessica A. Alvarez, Elizabeth Y. Chong, Douglas I. Walker, Joshua D. Chandler, Ellen S. Michalski, Ruth E. Grossmann, Karan Uppal, Shuzhao Li, Jennifer K. Frediani, Rabindra Tirouvanziam, ViLinh T. Tran, Vin Tangpricha, Dean P. Jones, Thomas R. Ziegler
Journal: Metabolism (2017)
Template-based high dose rate endobronchial brachytherapy for palliation of previously irradiated obstructive lung lesions.
Authors: Brian A Hrycushko, Hsienchang Chiu, Michael Ryan Folkert
Journal: Journal of Clinical Oncology (2016)

174 Background: Local progression after external beam radiation therapy (RT) for lung cancer may result in clinical compromise from bleeding and/or airway obstruction, and additional RT may be precluded by radiation tolerance. High-dose-rate (HDR) endobronchial brachytherapy (EBT) is an effective salvage treatment for airway obstruction and/or bleeding, but requires significant time and resources; planning and treatment are performed bronchoscopically under anesthesia. We sought to reduce procedure and anesthesia time for EBT through template-based planning. Methods: EBT templates were created using the Brachyvision version 11.0.47 treatment planning system for the Varisource iX Ir-192 afterloader. Plans were optimized for dose uniformity at distance from the source following planning criteria of published works. Nine endobronchial centering tube templates were created for treatment lengths from 2-10 cm (1cm intervals) prescribed to 0.5cm distance from the applicator surface. Results: Standard EBT treatment requires a median of 47 minutes (range 44-49 minutes); 5 minutes for applicator placement and fluoroscopic confirmation, 15-17 minutes for plan design and optimization, 20 minutes for quality assurance and plan check, 2-5 minutes for radiation delivery, and 2 minutes for room clearance and applicator removal. Pre-planned templates were evaluated for plan quality, and achieved &gt;90% of the prescription dose for the entire treatment length at the respective treatment depth. Changes to the prescription dose could be achieved through dwell time scaling. Changes to the prescription depth require re-optimization of the plan with the current templates as a base. Use of template-based planning was expected to reduce overall treatment time by 8-9 minutes (16-20% reduction in overall procedure time, 50-56% reduction in treatment planning time); median observed treatment time was 35 minutes (range 32-38 minutes). Conclusions: Template-based HDR EBT treatment plans were developed for the palliative lung cancer program at our institution. Implementation of template-based plans resulted in reduced procedure and operative time, and are now our standard technique.
Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis
Authors: Rachid Baz, Amila M Patel, Viet Q. Ho, Kenneth Shain, Melissa Alsina, Taiga Nishihori, Jose Leonel Ochoa-Bayona, Daniel Sullivan, Benjamin Djulbegovic, William S. Dalton
Journal: Blood (2011)
Applicability of Mini Nutritional Assessment as a predictor of survival in palliative chemotherapy
Authors: Sho Nakamura, Hiroto Narimatsu, Yuriko Sasahara, Kaname Watanabe, Hiroyuki Takeda, Shuhei Suzuki, Tadahisa Fukui, Takashi Yoshioka
Journal: Annals of Oncology (2016)
Phase I study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors.
Authors: Antonio Jimeno, Patricia LoRusso, Robert Matthew Strother, Jennifer Robinson Diamond, Leah Plato, Anne Younger, Wells A. Messersmith, Muaiad Kittaneh, Doug Sawyer, Lieve Adriaens, Liming Liu, Richard J. Kao, A Thomas DiCioccio, Carrie M. Brownstein, Israel Lowy, Pamela Trail, E. Gabriela Chiorean
Journal: Journal of Clinical Oncology (2013)

2502 Background: Dll4, a Notch receptor ligand, may have a role in tumor angiogenesis and is an emerging anticancer target. REGN421 (R) is a fully human IgG 1 mAb that binds human Dll4 and disrupts Notch-mediated signaling. Methods: Primary objectives of the dose escalation (3+3 design) trial were to determine safety and a recommended phase II dose (RP2D) of R in patients (pts) with advanced cancer. R was given IV at doses of 0.25, 0.5, 1, 2 and 4mg/kg every 3 weeks (Q3W) or 0.75, 1, 1.5, and 3mg/kg every 2 weeks (Q2W). Secondary objectives were PK, immunogenicity, and antitumor activity. Results: 53 pts (M/F=22/31, ECOG 0/1=18/35) were enrolled; 31 pts were treated Q3W at doses of 0.25 - 4 mg/kg; 22 pts were treated Q2W at doses of 0.75 - 3 mg/kg. Two DLTs occurred: Grade 3 (Gr3) nausea (0.5mg/kg Q3W) and Gr3 abdominal pain (1 mg/kg Q2W). A maximum tolerated dose was not reached on either schedule. Grade 3/4 AEs occurred in 29 pts; nausea, abdominal pain, dyspnea, hypoxia, and hypertension (HTN) were reported in ≥ 5%. Most frequent treatment related AEs were fatigue (30%), headache (26%), HTN (26%), and nausea (15%). Six treatment related SAEs (all reversed off treatment) were reported in 4 patients: BNP increase (0.25mg/kg, Gr1), troponin I increase (4mg/kg, Gr3), right ventricular dysfunction (1.5mg/kg, Gr3), left ventricular dysfunction (3mg/kg, Gr3) and 2 events of pulmonary HTN (1.5mg/kg, Gr 3, and 3mg/kg Gr3). Laboratory abnormalities (≥ Gr3) were neutropenia (3) and anemia (2), and elevated ALP (7), ALT (3), bilirubin (3), AST (2), and decreased albumin (1). Anti-tumor activity included 2 PRs (NSCLC BAL-type with a beta-catenin mutation and ovarian cancer [OvCa]), and 16 pts with SD (3 pts had SD &gt; 6 months). Two of 8 pts with OvCa had CA125 responses. R had non-linear target-mediated PK without accumulation. The half-life of R at 3mg/kg Q2W was 7 days. No immunogenicity was observed. Conclusions: REGN421 had an acceptable safety profile, and RP2Ds of 4mg/kg Q3W and 3mg/kg Q2W. Responses and prolonged SD were noted in OvCa pts and other solid tumors. Dose escalation has concluded and disease specific expansion cohorts are ongoing. Clinical trial information: NCT00871559.
[18F]Fluorodeoxyglucose PET/CT Predicts Response to Steroid Therapy in Constrictive Pericarditis
Authors: Sung-A Chang, Joon Young Choi, Eun Kyoung Kim, Seung Hyup Hyun, Shin Yi Jang, Jin-Oh Choi, Sung-Ji Park, Sang-Chol Lee, Seung Woo Park, Jae K. Oh
Journal: Journal of the American College of Cardiology (2017)
Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pN0) and limited node positive (pN+≤3) breast cancer (BC) patients (pts): First analysis of toxicity
Authors: E. G. C. Brain, T. Bachelot, D. Serin, Y. Graïc, J. C. Eymard, J. M. Extra, M. Combe, C. Nogues, J. Rouëssé
Journal: Journal of Clinical Oncology (2004)

617 Background Although recent results have shown the effectiveness of taxanes in the adjuvant treatment of BC, its influence is still under evaluation in most countries. . Methods The primary aim of this randomised trial was to determine whether 4 cycles of adjuvant AT (adriamycin 50 mg/m2 docetaxel 75 mg/m2) will prolong disease-free survival when compared to 4 cycles of AC (adriamycin 60 mg/m2 cyclophosphamide 600 mg/m2) in women age 18–70 with resected high-risk pN0 (Saint Gallen Consensus) or limited pN+ (≤ 3) invasive BC. Chemotherapy was delivered q3w without prophylactic filgrastim, followed by tamoxifen 20 mg/day for 5 years in pts with ER±PgR-positive tumours and radiation therapy according to standard guidelines. The trial planned to recruit 700 pts over 36 months. Results Between 6/1999 and 1/2003, 627 pts were randomised. Pt and tumour characteristics were well balanced between treatment groups: median age 52.2 years; premenopausal 47.9%; clinical tumour size ≤ 2.0/2.1–5 cm 53.5/42.8%; breast conserving surgery 71.8%; pN0/pN+ 43/57%; ER±PgR-positive 81.4%; SBR grade I/II/III 16.7/46.0/37.3%. The trial was closed in 1/2003 after the occurrence of a 2nd toxic death in the AT arm. With an 18-months median follow-up, we report safety data (table). In the AT arm, 1 pt developed perforative peritonitis requiring extensive surgery, and lethal toxicity occurred in 2 pts (1 mesenteric infarction and 1 colic perforation), all 3 with concomitant febrile neutropenia and septic shock. No grade 3–4 oedema or neurotoxicity. Conclusions With a high risk of life-threatening complications, AT combination is not easily manageable as such, without preventive strategies (e.g. filgrastim), especially in adjuvant setting and for an intermediate risk population. No significant financial relationships to disclose.
Final results of a phase II trial of R-IDEA as salvage therapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Authors: E. Kondo, K. Yamamoto, T. Masunari, J. Takizawa, K. Miura, Y. Masaki, T. Matsumura, Y. Hiramatsu, J. Murakam, H. Tsujimura, N. Tomita, Y. Maeda, M. Kanno
Journal: Annals of Oncology (2016)
Recall and uptake of survivorship care plan recommendations.
Authors: Andrew L. Salner, Deborah Walker, Amanda Seltzer, SarahLena Panzer, Carrie Stricker, Ellen A Dornelas
Journal: Journal of Clinical Oncology (2016)

67 Background: Despite the growing delivery of survivorship care plans (SCPs), little research has examined survivors’ recall and adoption of SCP recommendations, including those based on patient-reported symptoms and concerns. Methods: 65 stage 0-III breast cancer survivors participated in this pilot project. Patients completed an electronic patient-reported outcomes (ePRO) survey prior to a visit with a nurse practitioner, who delivered a tailored SCP generated by the Carevive Care Planning System (CPS) using evidence-based algorithms driven by ePRO and diagnosis/treatment data. Approximately 6 weeks later, patients completed a survey to evaluate their recall and any corresponding action taken. Actual SCP recommendations were extracted from the Carevive CPS database and matched to follow-up surveys to determine recall accuracy. Results: Data were analyzed for 35 patients completing follow-up surveys to date. SCPs contained an average of 22.2 recommendations per patient, almost half (n = 10.7) for active symptoms/supportive care issues. Recommendations were broken down into 3 groups 1) Surveillance, 2) Prevention, and 3) Intervention; see table below for select results. Of note, lymphedema-related recommendations were recalled accurately more often (p = 0.005) by those with symptoms vs. those advised on prevention. Conclusions: Incorporating an ePRO survey into SCP delivery enables tailoring to patient needs and concerns, which may in turn enhance recall and follow through given saliency. Patients tended to recall more accurately SCP recommendations for active or more severe symptoms. Additional research is needed to maximize retention and follow through on SCP recommendations. [Table: see text]
NIMG-34. 18FET-PET UPTAKE DYNAMICS SERVES AS AN ADDITIONAL IMAGING BIOMARKER IN ASTROCYTOMAS WITH IDH1/2 MUTATION AND NO LOH1p/19q
Authors: Bogdana Suchorska, Theo Kraus, Annamaria Biczok, Michael Weller, Marcus Unterrainer, Ulrich Schüller, Christine Schmid-Tannwald, Peter Bartenstein, Armin Giese, Nathalie Albert, Joerg-Christian Tonn
Journal: Neuro-Oncology (2016)

Stratification of glial tumors according to the presence of molecular features such as IDH1/2 mutation and loss of heterozygosity 1p/19q is gaining importance for tumor classification and treatment. In analogy, metabolic imaging such as 18FET-PET uptake dynamics reflected by time-to-peak (TTP) analysis allows discrimination between high-risk and low-risk glioma. The present study aims to investigate whether TTP offers additional prognostic information within this framework of molecular signature. 300 patients with a de-novo glioma WHO grade II-IV and 18FET-PET imaging at initial diagnosis were grouped according to IDH1/2 mutation and LOH 1p/19q status: IDH1/2 wildtype (wt) and IDH1/2mutant with or without co-deletion 1p/19q. Clinical and imaging factors such as age, Karnofsky Performance status, treatment and median TTP were analyzed for association with progression-free and overall survival (PFS and OS). 255 out of 300 (85%) patients showed 18FET-PET uptake. Molecular profile concerning IDH1/2 mutation and LOH 1p/19q status was available in 238 patients. The subgroup with IDH1/2 mutation and LOH 1p/19q had the best outcome concerning PFS and OS compared to IDH1/2 mutant /no LOH 1p/19q and IDH wt patients (p<0.0001 for PFS and OS). Median TTP values within the three subgroups were 12.5 minutes in the IDH 1/2 wt tumors and 25 min in both IDH 1/2 mutant tumors with/without LOH 1p/19q. TTP gained additional prognostic information in gliomas with IDH1/2mutation without LOH 1p/19q (p=0.03 for OS/PFS). 18FET-PET derived dynamic analysis using TTP delivers additional prognostic information concerning both progression-free and overall survival in the “astrocytic” subgroup of tumors with IDH1/2 mutation and no LOH 1p/19q. Thus, 18FET-PET uptake dynamics may serve as an additional imaging biomarker beyond the molecular signature.
Hyperthermic Isolated Pelvic Perfusion to Treat Pelvic Malignancies: First Russian Experience
Authors: Galina Kireeva, Ivan Yastrebov, Dmitry Surov, Alexey Belyaev, Ivan Solovyev, Alexandr Lopota, Konstantin Senchik, Dmitry Kandyba, Andrey Demko
Journal: Annals of Oncology (2016)
Association of Interleukin-6 Single Nucleotide Polymorphisms with Juvenile Idiopathic Arthritis
Authors: Sara Harsini, Vahid Ziaee, Marzieh Maddah, Mohammad Hassan Moradinejad, Arezou Rezaei, Samaneh Zoghi, Maryam Sadr, Nima Rezaei
Journal: Journal of Allergy and Clinical Immunology (2017)
Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) ± cobimetinib (COBI): A pooled analysis
Authors: P.A. Ascierto, A. Ribas, J. Larkin, G.A. McArthur, K.D. Lewis, A. Hauschild, K.T. Flaherty, E. McKenna, Q. Zhu, Y. Mun, B. Dréno
Journal: Annals of Oncology (2016)
Clinical features, outcomes, and prognostic factors in patients with extraskeletal osteosarcoma.
Authors: Sheila Thampi, Katherine K. Matthay, W. John Boscardin, Robert Goldsby, Steven G. DuBois
Journal: Journal of Clinical Oncology (2014)

10565 Background: Extraskeletal osteosarcoma (ESOS) is a rare subtype of osteosarcoma. We investigated patient characteristics, overall survival for ESOS as compared to skeletal osteosarcoma, and prognostic factors for ESOS. Methods: We identified cases of high-grade osteosarcoma with available data regarding tissue of origin (bone vs. soft tissue) in the Surveillance Epidemiology and End Results database from 1973 to 2009. Demographics were compared using chi-squared tests or t-tests. Overall survival was estimated using Kaplan-Meier methods and modeled using Cox proportional hazards methods. Competing risk analysis was utilized to determine differences in incidence of death from cancer. Results: 256 / 4,173 (6.1%) patients with high-grade osteosarcoma had ESOS. Patients with ESOS were more likely to be older, have axial tumors, have regional lymph node involvement (p<0.0001 for all comparisons), and be female (p=0.002). On univariate analysis, five-year overall survival for those with ESOS was inferior [37% (95% CI 30.6 to 43.3) vs. 50.8% (95%CI 49.1 to 52.50; p<0.0001]. However, on competing risk analysis, we found no difference in the cumulative incidence of death due to cancer between extraskeletal or skeletal osteosarcoma. This discrepancy was due to a significant interaction between age and tissue of origin such that older patients with ESOS had superior outcomes compared to older patients with skeletal osteosarcoma. On multivariate analysis of overall survival, ESOS was found to be favorable after controlling for differences in metastatic status, age, tumor site, gender, and year of diagnosis (hazard ratio 0.75; 95% CI 0.62 to 0.90; p=0.002). Independent adverse prognostic factors in patients with ESOS include distant metastatic disease, larger tumor size, older age, and axial tumor site. Conclusions: This analysis reveals distinct patient characteristics in ESOS but similar prognostic factors between ESOS and skeletal osteosarcoma. Contrary to previous reports, the incidence of death from osteosarcoma is similar between both types of osteosarcoma. While older patients have poor overall survival with high-grade osteosarcoma, extraskeletal origin predicts better outcomes.
Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity
Authors: Perrine Guillaume-Jugnot, Zora Marjanovic, Myriam Labopin, Louis Terriou, Christophe Deligny, Bruno Lioure, Thierry Martin, Veronique Leblond, Gregory Pugnet, Didier Blaise, Régis Peffault de Latour, Ibrahim Yakoub-Agha, John A Snowden, Dominique Farge
Journal: Blood (2015)
P19.01 Is reduced dose craniospinal radiation safe in adult medulloblastoma?
Authors: D. Frappaz, M. Sunyach, E. Le Rhun, E. Le Rhun, F. Laigle Donadey, A. Bonneville Levard, M. Massimino
Journal: Neuro-Oncology (2016)

Medulloblastomas is an orphan disease in adults. Standard treatment of completely removed localised adult medulloblastoma includes a craniospinal, irradiation with 36 Gy to axis and 54 Gy to whole posterior fossa. Pediatric randomized study demonstrated that a decreased dose of 24 Gy to axis with 54 Gy limited to tumoral bed gives similar result as standard therapy, provided chemotherapy is associated. May this pediatric experience be extended to adult population? Material: we retrospectively collected data of all adult patients with standard risk medulloblastoma treated with chemotherapy + reduced dose craniospinal irradiation (24 Gy to axis+ boost up to 54 Gy to tumoral bed) issued from 4 institutions. Results: 34 patients received various chemotherapies: 8 drug in 1 day (2 courses before and after RT in 3 patients) VP 16 CARBOPLATINE (2 courses before and after RT in 14 patients) or CCNU-Cisplatin-Vincristin (8 courses after RT in 17 patients), with reduced dose craniospinal irradiation. With a median follow up of 58 months, the 5 and 10 years PFS was respectively 85+/-8% and 75+/-12%. The 5 and 10 year overall survival was 94+/-6 and 79+/-11% respectively. Four patients relapsed, 3 locally, and one locally and in CSF. Median progression time were 53 months. Conclusion: These results compare favorably with those of the HIT protocol (73% 5-year PFS) using standard dose of radiation to axis {Friedrich, Eur J Cancer 2013}.Thus chemotherapy with reduced dose of CSI is feasible in adult medulloblastoma with standard risk. This may serve as a basis for future randomized trials.
Zanolimumab, a Fully Human Monoclonal Antibody: Early Results of an Ongoing Clinical Trial in Patients with CD4+ Mycosis Fungoides (MF) Type CTCL (Stage IB-IVB) Who Are Refractory or Intolerant to Targretin and One Other Standard Therapy.
Authors: Madeleine Duvic, Youn Kim, Neil J. Korman, Erin Boh, Adam Lerner, Michael P. Heffernan, Kenneth B. Hymes, Theresa Pacheco, Craig A. Elmets, Steen Lisby, Ole Baadsgaard
Journal: Blood (2006)
Widespread activity of multiple lineages of Usutu virus, western Europe, 2016
Authors: Daniel Cadar, Renke Lühken, Henk van der Jeugd, Mutien Garigliany, Ute Ziegler, Markus Keller, Jennifer Lahoreau, Lars Lachmann, Norbert Becker, Marja Kik, Bas B Oude Munnink, Stefan Bosch, Egbert Tannich, Annick Linden, Volker Schmidt, Marion P Koopmans, Jolianne Rijks, Daniel Desmecht, Martin H Groschup, Chantal Reusken, Jonas Schmidt-Chanasit
Journal: Eurosurveillance (2017)

In the summer of 2016, Belgium, France, Germany and the Netherlands reported widespread Usutu virus (USUV) activity based on live and dead bird surveillance. The causative USUV strains represented four lineages, of which two putative novel lineages were most likely recently introduced into Germany and spread to other western European countries. The spatial extent of the outbreak area corresponded with R 0 values &gt; 1. The occurrence of the outbreak, the largest USUV epizootic registered so far in Europe, allowed us to gain insight in how a recently introduced arbovirus with potential public health implications can spread and become a resident pathogen in a naïve environment. Understanding the ecological and epidemiological factors that drive the emergence or re-emergence of USUV is critical to develop and implement timely surveillance strategies for adequate preventive and control measures. Public health authorities, blood transfusion services and clinicians in countries where USUV was detected should be aware of the risk of possible USUV infection in humans, including in patients with unexplained encephalitis or other neurological impairments, especially during late summer when mosquito densities peak.
Infusion Speed-Escalation Trial To Give Full-Dose Rituximab in One Hour without Steroids Pre-Medication.
Authors: Michele Ghielmini, Laura Negretti, Erika Lerch, Barbara Roth, Michèle Voegeli, Tatiana Terrot, Flavia Pandiani, Emanuele Zucca, Cristiana Sessa
Journal: Blood (2005)
Novel Evidence for the Presence of Potent, Paracrine, Pro-Angiopoietic Effects of Purified Human Umbilical Cord Blood-Derived CD133+ Cells - Implications for Adult Stem Cell Therapies in Regenerative Medicine
Authors: Kasia Mierzejewska, Magdalena Kucia, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2012)
Title: PAI-1 Gain of Function Genotype and Airway Obstruction in Asthma
Authors: Michael G. Sherenian, Seong Ho Cho, Albert M. Levin, Jin Young Min, Saunak Sen, Sam Oh, Scott Huntsman, Celeste Eng, Harold J. Farber, William Rodriguez-Cintron, Jose R. Rodriguez-Santana, Denise Serebrisky, Luisa Borrell, L. Keoki Williams, Shannon Thyne, Max A. Seibold, Esteban Burchard, Rajesh Kumar
Journal: Journal of Allergy and Clinical Immunology (2017)
Clonal Heterogeneity in TEL/AML1+ Acute Lymphoblastic Leukemia (ALL): A Clinical Appraisal
Authors: Stefanos I Papadhimitriou, Anna Paisiou, Nikolaos Tsagarakis, Vassilios Papadakis, Nektaria Kentrou, Georgios Paterakis, Agapi Parcharidou, Anastasia A Tsakiridou, Konstantinos Tsitsikas, Ioannis Kostopoulos, Dimitrios Pavlidis, Maria Georgiakaki, Sophia Polychronopoulou
Journal: Blood (2008)
Gene Expression Profiling Reveals Genes Predictive of Outcome In Infant Acute Lymphoblastic Leukemia (ALL) and Distinctive Age-Related Gene Expression Profiles (&lt; 90 Days vs. &gt; 90 Days): A Children's Oncology Group Study
Authors: Huining Kang, Carla S. Wilson, Richard C. Harvey, I-Ming Chen, Maurice H. Murphy, Susan R. Atlas, Edward J. Bedrick, Meenakshi Devidas, Andrew J. Carroll, Blaine W. Robinson, Nyla A. Heerema, Joanne M. Hilden, Zoann E. Dreyer, Bruce Camitta, Naomi Winick, William L. Carroll, Carolyn A. Felix, Gregory H. Reaman, Stephen P. Hunger, Cheryl L. Willman
Journal: Blood (2010)